A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Corpus Uteri | Ovary
What is the purpose of this trial?
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- GenderFemale only
- Trial withSutro Biopharma Inc.
- Start Date12/21/2021
- End Date08/31/2022
- Last Updated12/22/2021
- Study HIC#2000030071